Sunday, 24 August 2014


This is copied from Dr Robert Bransfield's Facebook page but much of the content is being shared on Facebook from many sources.

CDC Fraud Exposed
The trade marked phrase of the CDC is “Saving Lives, Protecting People” however failures within the CDC have resulted in a number of major failures such as biohazard lab failures, the high titer Edmonston-Zagreb measles vaccine studies and the financially biased and scientifically unsound reliance upon the poor quality two tiered Lyme disease testing.
A recent peer reviewed article by BS Hooker demonstrates the concerns about the MMR vaccine noted by Andrew Wakefield had scientific validity and the attempts to discredit him had not scientific merit. The article is called: Measles-mumps-rubella vaccination timing and autism among young African American boys: a reanalysis of CDC data and is posted on MedLine at: A vide expanding upon the issues is at: Since the video has been released it has started a firestorm of controversy: We need better safeguards to prevent current CEDC fraud. It currently exists in regard to Lyme disease and a thorough investigation is needed.
I copy the NIH study below
Transl Neurodegener. 2014 Aug 8;3:16. doi: 10.1186/2047-9158-3-16. eCollection 2014.

Measles-mumps-rubella vaccination timing and autism among young african american boys: a reanalysis of CDC data.



A significant number of children diagnosed with autism spectrum disorder suffer a loss of previously-acquired skills, suggesting neurodegeneration or a type of progressive encephalopathy with an etiological basis occurring after birth. The purpose of this study is to investigate the effectof the age at which children got their first Measles-Mumps-Rubella (MMR) vaccine on autism incidence. This is a reanalysis of the data set, obtained from the U.S. Centers for Disease Control and Protection (CDC), used for the Destefano et al. 2004 publication on the timing of the first MMR vaccine and autism diagnoses.


The author embarked on the present study to evaluate whether a relationship exists between child age when the first MMR vaccine was administered among cases diagnosed with autism and controls born between 1986 through 1993 among school children in metropolitan Atlanta. The Pearson's chi-squared method was used to assess relative risks of receiving an autism diagnosis within the total cohort as well as among different race and gender categories.


When comparing cases and controls receiving their first MMR vaccine before and after 36 months of age, there was a statistically significant increase in autism cases specifically among African American males who received the first MMR prior to 36 months of age. Relative risks for males in general and African American males were 1.69 (p=0.0138) and 3.36 (p=0.0019), respectively. Additionally, African American males showed an odds ratio of 1.73 (p=0.0200) for autism cases in children receiving their first MMR vaccine prior to 24 months of age versus 24 months of age and thereafter.


The present study provides new epidemiologic evidence showing that African American males receiving the MMR vaccine prior to 24 months of age or 36 months of age are more likely to receive an autism diagnosis.


Autism; Measles-mumps-rubella (MMR) vaccine 

Just recently this was published 

Med Hypotheses. 2014 Jun 16. pii: S0306-9877(14)00233-3. doi: 10.1016/j.mehy.2014.06.005. [Epub ahead of print]

Divergent opinions of proper Lyme disease diagnosis and implications for children co-morbid with autism spectrum disorder.


This paper proposes that some children with an autism spectrum disorder (ASD) in the United States have undiagnosed Lyme disease and different testing criteria used by commercial laboratories may be producing false negative results. Two testing protocols will be evaluated; first, the Centers for Disease Control (CDC) and Infectious Disease Society of America (IDSA) approved two-tiered Enzyme Immunoassay (EIA) or Immunofluorescence Assay (IFA) followed by an IgM and/or IgG Western Blot test. Second, a clinical diagnosis (flu like symptoms, joint pain, fatigue, neurological symptoms, etc.) possibly followed by a Western Blot with a broader criteria for positive bands [1]. The hypothesis proposes that the former criteria may be producing false negative results for some individuals diagnosed with an ASD. Through an online survey parents of 48 children who have a diagnosis of an ASD and have been diagnosed with Lyme disease were asked to fill out the Autism Treatment Evaluation Checklist (ATEC) before they started antibiotic therapy and after treatment. Of the 48 parents surveyed 45 of them (94%) indicated their child initially tested negative using the two-tiered CDC/IDSA approved test. The parents sought a second physician who diagnosed their child with Lyme disease using the wider range of Western Blot bands. The children were treated with antibiotics and their scores on the ATEC improved. Anecdotal data indicated that some of the children achieved previously unattained developmental milestones after antibiotic therapy began. Protein bands OSP-A and/or OSP-B (Western Blot band 31) and (Western Blot band 34) were found in 44 of 48 patients. These two bands are so specific to Borrelia burgdorferi that they were targeted for use in vaccine trials, yet are not included in the IDSA interpretation of the Western Blot.
Copyright © 2014. Published by Elsevier Ltd.

and also interesting to hear Dr Jones Interview where he also discusses Lyme and Vaccination  in Autistic children too long to copy

Saturday, 2 August 2014


New Standard of Care Guidelines for Treating Lyme and Other Tick-borne Illnesses Released by International Lyme and Associated Diseases Society (ILADS)

Bethesda, Maryland, July 31, 2014
How doctors treat patients with suspected Lyme infections needs to change so as to avoid potential long term illness and suffering.  To that end, the International Lyme and Associated Diseases Society (ILADS) today released updated guidelines for the treatment of Lyme and other tick borne infections which call on physicians to provide evidence-based, patient-centered care for those with Lyme disease.
Published in the August 2014 edition of the journal Expert Review of Anti-infective Therapythe new guidelines, titled: Evidence Assessments and Guideline Recommendations in Lyme disease: The Clinical Management of Known Tick Bites, Erythema Migrans Rashes and Persistent Disease, say current antibiotic protocols used by many physicians to prevent or treat Lyme disease are inadequate, leading to an increased risk of Lyme disease developing into a chronic illness.
“Chronic manifestations of Lyme disease can continue long after other markers of the disease, such as the erythema migrans rash, have resolved,” said Daniel Cameron, M.D., M.P.H., and lead author. “Understanding this reality underlies the recommendation for careful follow-up to determine which individuals with Lyme disease could benefit from additional antibiotic therapy.”
 ILADS is the first organization to issue guidelines on Lyme disease which comply with the standards set by the Institute of Medicine for developing trustworthy protocols. The document provides a rigorous review of the pertinent medical literature and contains recommendations for Lyme disease treatment based on the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) process. This review format is used by other well-respected medical organizations including the Cochrane Collaboration and the World Health Organization.
ILADS’ GRADE-based analyses discovered research studies guiding current treatment protocols were of very low quality; and, the regimens based on these randomized controlled trials often failed.  “For this reason, we moved away from designating a fixed duration for antibiotic therapy for tick borne illnesses and instead encourage clinicians to tailor therapy based on the patient’s response to treatment,” noted Dr. Cameron.
“We not only recommend clinicians perform a deliberate and individualized assessment of the potential risks and benefits of various treatment options before making their initial selection,”  said guidelines coauthor Elizabeth Maloney, M.D., “we also recommend careful follow-up. Monitoring a patient allows clinicians to adjust therapy as circumstances evolve. This more selective approach should reduce the risk of inadequate treatment giving rise to a chronic illness,” added Dr. Maloney.
The guidelines encourage shared medical decision making and taking patient values into consideration. Lorraine Johnson, J.D., MBA, a coauthor and Executive Director of, noted, “A lot of the treatment decisions in Lyme disease depend on trade-offs. How sick is the patient? How invasive is the treatment? What is valued by the patient? Patients need to understand the risks and benefits of treatment options to make informed medical choices,” added Ms. Johnson. “These guidelines provide that information.”
ILADS is a nonprofit, international, multidisciplinary medical society dedicated to the appropriate diagnosis and treatment of Lyme and associated diseases.
For more information:
Further article on Lyme 
Next section
Evidence-based guidelines for the management of patients with Lyme disease were developed by the International Lyme and Associated Diseases Society (ILADS). The guidelines address three clinical questions – the usefulness of antibiotic prophylaxis for known tick bites, the effectiveness of erythema migrans treatment and the role of antibiotic retreatment in patients with persistent manifestations of Lyme disease. Healthcare providers who evaluate and manage patients with Lyme disease are the intended users of the new ILADS guidelines, which replace those issued in 2004 (Exp Rev Anti-infect Ther 2004;2:S1–13). These clinical practice guidelines are intended to assist clinicians by presenting evidence-based treatment recommendations, which follow the Grading of Recommendations Assessment, Development and Evaluation system. ILADS guidelines are not intended to be the sole source of guidance in managing Lyme disease and they should not be viewed as a substitute for clinical judgment nor used to establish treatment protocols.

Monday, 21 July 2014


Alzheimer Borreliosis Lecture London June 4 2014
Dr Alan MacDonald 

Published on Jul 17, 2014
Infection Induced Human Dementias are briefly reviewed,.Tertiary Syphilitic 
Dementia ( General Paresis) is reviewed and comparisons with Tertiary Spirochetal Human infections , dementing types. (Leptospirosis-NEJM 2014, Treponema pallidum, Borrelia burgdorferi family of spirochetes, and other Oral Treponemes.
The Conclusion Formulation by Dr. Alan MacDonald, MD is that
Alzheimer's disease of the Subtype caused by Tertiary Neuroborreliosis
demonstrates Evidence by Borrelia specific DNA Probe analysis and by 
Microbiologic cultures of Autopsy Alzheimer's Brain tissues producing
live Borrelia in pure culture, that Alzheimer's of the Tertiary Borreliosis type
is a infectious disease. The Plaques in such cases are Borrelia biofilm communities.
Granular Vacuolar lesions of the Hippocampus are granular borrelia
which contain Borrelia DNA and which Bind Borrelia specific DNA tissue
probes with In Situ DNA Hybridization in Autopsy studies.
The Borrelia infection subtype of Alzheimer's, in like manner with with
Treponema pallidum induced Dementia in late disease has the potential to to
be cured by antibiotic therapies. 

The above lecture was given at the Inaugural Meeting of the Spirochetal Alzheimer Association link here

Friday, 18 July 2014


Borrelia miyamotoi in host-seeking Ixodes ricinus ticks in England.

Link to the paper on Pubmed here  

 2014 Jul 14:1-9. [Epub ahead of print]

Borrelia miyamotoi in host-seeking Ixodes ricinus ticks in England.


SUMMARY This paper reports the first detection of Borrelia miyamotoi in UK Ixodes ricinus ticks. It also reports on the presence and infection rates of I. ricinus for a number of other tick-borne pathogens of public health importance. Ticks from seven regions in southern England were screened for B. miyamotoi, Borrelia burgdorferi sensu lato (s.l.), Anaplasma phagocytophilum and Neoehrlichia mikurensis using qPCR. A total of 954 I. ricinus ticks were tested, 40 were positive for B. burgdorferi s.l., 22 positive for A. phagocytophilum and three positive for B. miyamotoi, with no N. mikurensis detected. The three positive B. miyamotoi ticks came from three geographically distinct areas, suggesting a widespread distribution, and from two separate years, suggesting some degree of endemicity. Understanding the prevalence of Borrelia and other tick-borne pathogens in ticks is crucial for locating high-risk areas of disease transmission.
[PubMed - as supplied by publisher] 

Borrelia miyamotoi found in ticks in England is of significant importance because of problems over testing

Lyme Disease Action  discusses Borrelia Miyamotoi in this article here 

Illness following Tick bites may not always be identified by blood tests, essentially 
doctors may have to make a clinical diagnosis and treat empirically 

An excellent source of information for clinicians and patients is Lyme Disease Action 

Wednesday, 16 July 2014


Dr. Joseph G. Jemsek, MD, FACP, AAHIVS was a Keynote Speaker at the Partners Against Lyme and Tick Associated Diseases' Inaugural Forum on October 5th, 2013.

Inspirational speech - Dr Jemsek's journey treating Lyme Disease 

Dr Jemsek came to London in June and presented at the London Symposium on Tick borne disease to an audience of doctors, researchers and vets.

An earlier post Dr Jemsek discussing the Physician Training Program link here 

and Dr Jemsek  'Speak the truth speech'  link here 

Monday, 14 July 2014


An Open Letter to Martin Andersson and Richard Birtles.

Your presentations at the recent Lyme Disease Action conference at the University of Surrey were particularly impressive and obviously the results of countless hours of effort from you and your co-workers. The information regarding the transmission pathways of tick-borne pathogens highlighted the differences of risk to human health from the different species of ticks, and help define optimum strategies for disease prevention. It also demonstrated the variability of tick infection rates on geographic macro and micro scales. Of great interest was the ingenious study of forest enclosures and tick infection rates within and outside the barriers. Deer population size was a driver of tick populations, and rodents a driver for tick infection rates. This suggests that areas with large populations of mammals that provide the final feed for adult female ticks along with high populations of rodents, will have high numbers of infected ticks.

The study of Candidatus Neoehrlichia mikurensis is important in highlighting the fact that ticks carry many different microbes, and new species are being discovered all the time. More than 18 distinct species of Borrelia bacteria have been identified since Willy Burgdorfer first identified the cause of Lyme disease in the early 1980’s. There can be long delays between identification of an organism and general recognition as a disease causing pathogen. It is normal to describe incidence of disease based on national or regional boundaries, however it was well demonstrated in the presentation that absence of reported cases does not mean absence of the disease, and the fact that until you look you will not find. Has the genetic divergence seen in China compared to that exhibited in Europe been used to estimate the length of time that Neoehrlichia has been present in these regions?

Both presentations highlight the fact that ticks do not recognise boundaries marked on maps. It is whether the ecological conditions exist at a specific location that drives the occurrence of infected ticks. Fragmentation of woodland created by urban expansion and people living adjacent to woodlands, parkland and other tick habitat results in large numbers of people and their companion animals permanently living in close proximity to ticks. There could be a higher risk living at 201 Sunnyside Avenue with 2 dogs than an occasional visit to our magnificent countryside.

Clinicians officially have 10 minutes to decide what ails a person, and if Lyme is suspected then it is convenient to enquire whether the person visited a hot spot defined regionally such as, The New Forest, or Dartmoor or Thetford Forest. It may be more relevant to ask; do you live or play near woodland or areas of natural beauty. This is not an easy option to implement when we are so conditioned to arbitrary lines marked on maps. Can a method other than the use of title specific regions be developed to help clinicians assess the risk of infection? Or should the concept of “hot spots” be abandoned and replaced by a greater emphasis on clinical symptoms?

It is hard work and scientific data gathering and analysis as demonstrated by you, that will help educate current and future generations and reduce or avoid the often devastating and sometimes fatal effects of tick-borne diseases.

Michael Cook

Friday, 11 July 2014


Dr Stephen Barthold interview on Lyme disease From CBC Ticked Off The Mystery of Lyme Disease - expert interviews found on the right hand side of this link here

Persistence of Lyme Disease bacteria has been much in the news recently with CDC/NIH Webinar posted earlier here 

The previous post to this on persisters here

Another interesting presentation from Dr Barthold can be found here